Navigation Links
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Date:4/14/2008

gh pain who experienced between one and four episodes of breakthrough pain per day and who were already taking maintenance opioid therapy. An extension study has demonstrated safety and tolerability in 197 patients followed over a six-month period.

In September 2006, the fentanyl buccal tablet formulation was approved in the United States under the trade name FENTORA(R) (fentanyl buccal tablet) [C-II].

About Breakthrough Cancer Pain

An estimated 3 million new cases of cancer were diagnosed in Europe in 2006. In patients with cancer, chronic pain often has two components: persistent pain and breakthrough cancer pain. Breakthrough pain is an intense transient flare of pain that interrupts or "breaks through" their persistent pain. The onset of breakthrough cancer pain is often sudden, reaches peak intensity within three minutes, and lasts for a median duration of 30 minutes. Patients may have up to four episodes of breakthrough pain per day. Episodes may occur during a specific activity or incident or spontaneously with no apparent cause.

Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, TRISENOX(R) (arsenic trioxide) injection, TREANDA(R) (bendamustine hydrochloride), AMRIX(R) (cyclobenzaprine hydrochlori
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
5. Cephalon General Counsel John E. Osborn to Resign Position
6. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
7. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
8. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
9. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
10. Cephalon Submits Supplemental New Drug Application for FENTORA
11. Cephalon Announces Strong Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 Berkshire Corporation, the world ... announce the release of the ValuSeal® IonX™ cleanroom ... contamination containment in critical processing applications. , Recommended ... cleanroom environments, ValuSeal® IonX™ is a laser sealed ... that continues Berkshire’s innovative focus on meeting new ...
(Date:10/25/2014)... LONDON , October 24, 2014 ... CytRx Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals ... (NASDAQ: ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 23, 2014, ended on a positive ...
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution ... pain management and clinical markets. The software increases the ... allowing users to highlight and review results that are ... analysts to filter results by group or based on ... the need to sift through analytes of no interest. ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2
... 2011 Neogen Corporation (Nasdaq: NEOG ) announced ... 2012, which ended Aug. 31, increased 6.5% to $45,697,000, from ... year,s revenue increase is almost entirely comprised of products available ... net income increased 3.1% from the prior year to $6,004,000, ...
... N.C. -- Copper nanowires may be coming to a little ... to drive down the costs of displaying information on cell ... build foldable electronics and improved solar cells, according to new ... have developed a technique to organize copper atoms in water ...
... ANNAPOLIS, Md., Sept. 26, 2011 PharmAthene, Inc. (NYSE ... medical countermeasures against biological and chemical threats, today announced ... Board of Directors, effective September 22, 2011. ... President and Chief Executive Officer for Nycomed U.S. which will be ...
Cached Biology Technology:Neogen Reports First Quarter Revenue and Net Income Increases 2Neogen Reports First Quarter Revenue and Net Income Increases 3Neogen Reports First Quarter Revenue and Net Income Increases 4Neogen Reports First Quarter Revenue and Net Income Increases 5Copper film could lower touch screen, led and solar cell costs 2PharmAthene Appoints Brian A. Markison to the Company's Board of Directors 2PharmAthene Appoints Brian A. Markison to the Company's Board of Directors 3
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... shown for the first time how bacteria can grow ... them the opportunity to get tremendous insights into bacteria ... also discovered the bacterial growth in chronic lung infections ... down by the immune cells. The researchers discovered the ... the bacteria, forcing the bacteria to switch to a ...
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2
... and misunderstandings frequently arise between individuals from different cultures. ... restrictive and another less so? A new international ... by the National Science Foundation,s Division of Behavioral and ... cultural differences and bridge the gaps between them. ...
... cause neurodegenerative prion diseases may require a genetic key, ... Chicago distinguished professor of biological sciences Susan Liebman. ... form. One prion in mammals promotes progressive neurodegenerative disorders ... how this process happens remains an open question for ...
... Calif., May 26, 2011 Epitomics, Inc. announced today ... Schering Pharma AG, Germany (Bayer HealthCare). Epitomics will use ... for Bayer HealthCare,s drug target identification and validation. ... Bayer HealthCare. This new agreement is a major expansion ...
Cached Biology News:World-wide assessment determines differences in cultures 2World-wide assessment determines differences in cultures 3Study finds 2 gene classes linked to new prion formation 2
... Molecular Imaging Systems group announces the ... Digital Imaging Systems, featuring high resolution ... fluorescence, luminescence, radiographic and chromogenic imaging ... CCD and 10x optical zoom lens ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
... for the extraction of unwanted detergent ... macromolecules, Applications: ,Reducing octyl glucoside concentration ... of pure β-adrenergic receptor and pure ... in 6 M urea/0.05 mM Tris ...
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
Biology Products: